NEW YORK, Aug. 6 (GenomeWeb News) - Story Landis has been appointed director of the National Institute of Neurological Disorders and Stroke, the NIH said today.
Landis, the current scientific director of the NINDS intramural program, will begin to serve as NINDS director September 1. She will oversee an annual budget of $1.5 billion and a staff of over 900 scientists, the NIH said.
Landis has been at NINDS since 1995, when she joined as scientific director. She was also named president-elect of the Society for Neuroscience in 2002. Before that, Landis was chairman of the Department of Neurosciences at Case Western Reserve University School of Medicine. She also previously held a position on the faculty of the Harvard Medical School Department of Neurobiology.
Robert Johnson has been named president and chief operating officer of Spectral Genomics, the Houston-based microarray company said Aug. 4.
Johnson was most recently chief operating officer and chief scientific officer at VitaGen, a cell therapy company. Prior to that, he was senior research director of the gene therapy business unit at Baxter Healthcare, where he worked for 18 years.
Frank McCormick has joined the board of directors at Exelixis, of South San Francisco, and Peter Stadler has resigned from the board, the company said July 31.
McCormick is director of the University of California, San Francisco Comprehensive Cancer Center and a professor of tumor biology and cancer research in the UCSF department of microbiology. Prior to joining UCSF, McCormick was a founder and chief scientific officer at Onyx Pharmaceuticals, and has also held positions of vice president of research at Chiron and vice president of research at Cetus.
Stadler, who is managing director and a co-founder of Artemis Pharmaceuticals, has been a board member of Exelixis since 1998. He is also a former executive of Bayer, and currently serves on the board of the European Biotechnology Association, based in Brussels.